BRAF, a member of a serine/threonine kinase protein family, serves as an immediate downstream effector of RAS in the MAPK signaling cascade, a signal transduction pathway that transmits mitogenic ...

[40] This emphasizes the importance of knowing not only a patient's BRAF mutant status, but also RAS mutant status and highlights the potential for several growth pathways to influence one another ...

Building on this research, Professors Marshall and Richard Marais – who at the time was a colleague at the ICR – conducted further experiments on the pathway. They predicted that a protein called BRAF ...

One of the standard treatment options for melanoma over the last 10 years has been to simultaneously target both BRAF ...

Data from several groups show, in fact, that PLX4032 paradoxically activates BRAF signaling in normal cells. This pathway activation enhances the therapeutic window, but also probably leads to the ...

Erasca has streamlined its pipeline, now focusing on a phase 3 trial for Naporafenib targeting NRAS-mutant melanoma. Read ...

The MSc Education (Open Pathway) allows you to design your own programme of study based on your areas of interest, rather than choosing one subject area from our specialist pathways. Units can be ...

In consultation with your academic advisor - utilize the worksheet below to assist you in selecting appropriate and valid paths while navigating the Path Finder tool. If you need an accessible version ...

On Thursday, Pasithea Therapeutics Corp. (NASDAQ:KTTA) announced safety, tolerability, pharmacokinetic (PK), and preliminary ...

NEW YORK, Sept 14 (Reuters) - Pfizer (PFE.N), opens new tab is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the ...

The advent of large-scale sequencing in both development and disease has identified large numbers of candidate genes that may be linked to important phenotypes. Validating the function of these ...